This site is intended for New Zealand consumers only.
Keep using your asthma medication as prescribed by your doctor until they tell you to change. Your doctor may prescribe Symbicort Turbuhaler in a different way or for a different indication to that which is described here. Follow your doctors directions carefully. Usually you do not feel any side effects when you use Symbicort. The most common side effects of Symbicort are mild irritation in the throat, coughing, hoarseness, thrush (of mouth or throat), headache, tremor, palpitations and pneumonia (in COPD patients). Tell your doctor if any of these or other unusual effects bother you.
Symbicort® is a prescription medicine for the treatment of asthma and COPD. For asthma: Anti-inflammatory reliever therapy (Symbicort 200/6); Anti-inflammatory reliever plus maintenance therapy (Symbicort 100/6; 200/6), maintenance therapy (Symbicort 100/6, 200/6, 400/12). For COPD (Symbicort 200/6, 400/12). Symbicort® has risks and benefits. Ask your doctor if Symbicort® is right for you. Use strictly as directed. If symptoms persist see your doctor. Symbicort® is fully funded on the Pharmaceutical Schedule. Normal doctor’s charges and pharmacy fees apply. Ingredients: budesonide/formoterol 100mcg/6mcg, 200/mcg/6mcg, 400mcg/12mcg. For product details check the Consumer Medicine Information, CMI, at www.medsafe.govt.nz.
References: 1. SYMBICORT Turbuhaler Consumer Medicine Information. Available from https://www.medsafe.govt.nz/Consumers/cmi/s/SymbicortThaler.pdf. Last accessed 10 December 2019. 2. SYMBICORT Turbuhaler Data Sheet NZ. 3. National Asthma Council (NAC). Australian Asthma Handbook V2.1. Guide to Reliever Medicines. 2020. Available at: https://www.asthmahandbook.org.au/resources/medicines-guide/relievers. Last accessed 09 September 2020. 4. Asthma and Respiratory Foundation NZ. What is Asthma? Available from https://www.asthmafoundation.org.nz/your-health/living-with-asthma. Last accessed on 9 December 2019. 5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: Updated 2019: Available from https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Last accessed 3 December 2019. 6. Asthma and Respiratory Foundation NZ: NZ Adolescent and Adult Asthma Guidelines 2020. Available from https://www.nzrespiratoryguidelines.co.nz/uploads/8/3/0/1/83014052/arfnz_adolescent_and_ad ult_asthma_guidelines_.pdf. Last accessed 24 July 2020. 7. Asthma and Respiratory Foundation NZ. Reliever Inhalers. Available from https://www.asthmafoundation.org.nz/your-health/living-with-asthma/asthma-medication/reliever-inhalers. Last accessed on 3 June 2019. 8. SYMBICORT Turbuhaler NZ Instructions for Use
Symbicort,® Turbuhaler® and Bricanyl® are trademarks of the AstraZeneca Group of companies. Ventolin® is a registered trademark of GlaxoSmithKline group company. SalAir® is a registered trademark of Rex Medical. Respigen™ is a trademark of Mylan. Registered user AstraZeneca Limited, PO Box 87453, Meadowbank, Auckland 1742.
For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone (09) 306 5650 or via https://contactazmedical.astrazeneca.com or email Medical Information enquiries to firstname.lastname@example.org
NZ-1371. TAPS NA 12734. May 2021